Clinical Trial Update: Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating linperlisib in combination with an EZH2 inhibitor for relapsed/refractory peripheral T-cell lymphoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• EZH2 inhibitor
• Linperlisib (linperlisib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Peripheral T Cell Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING